idebenone has been researched along with Respiration Disorders in 3 studies
Respiration Disorders: Diseases of the respiratory system in general or unspecified or for a specific respiratory disease not available.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with idebenone was safe and well tolerated with adverse event rates were similar in both groups." | 2.80 | Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. ( Bernert, G; Buyse, GM; Cuisset, JM; D'Angelo, MG; Finkel, RS; Goemans, N; McDonald, CM; Meier, T; Rummey, C; Schara, U; Straathof, CSM; Voit, T, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Servais, L | 1 |
| Straathof, CSM | 2 |
| Schara, U | 2 |
| Klein, A | 1 |
| Leinonen, M | 1 |
| Hasham, S | 1 |
| Meier, T | 2 |
| De Waele, L | 1 |
| Gordish-Dressman, H | 1 |
| McDonald, CM | 2 |
| Mayer, OH | 1 |
| Voit, T | 2 |
| Mercuri, E | 2 |
| Buyse, GM | 2 |
| Muntoni, F | 1 |
| D'Angelo, MG | 1 |
| Bernert, G | 1 |
| Cuisset, JM | 1 |
| Finkel, RS | 1 |
| Goemans, N | 1 |
| Rummey, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids[NCT02814019] | Phase 3 | 255 participants (Actual) | Interventional | 2016-09-30 | Terminated (stopped due to Interim analysis concluded to futility) | ||
| A Phase III Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in 10-18 Year Old Patients With Duchenne Muscular Dystrophy[NCT01027884] | Phase 3 | 65 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Who Completed the SIDEROS Study[NCT03603288] | Phase 3 | 161 participants (Actual) | Interventional | 2018-07-04 | Terminated (stopped due to Interim analysis concluded to futility of main study SIDEROS (SNT-III-012)) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 52 (NCT01027884)
Timeframe: Baseline and Week 52
| Intervention | percentage of Predicted FVC (Mean) |
|---|---|
| Placebo | -8.95 |
| Idebenone | -5.67 |
Change from Baseline in Percent Predicted Peak Expiratory Flow (PEF) at Week 52 (NCT01027884)
Timeframe: Baseline and Week 52
| Intervention | percentage (Geometric Mean) |
|---|---|
| Placebo | -8.84 |
| Idebenone | -2.57 |
"PedsQL Quality of Life Inventory contains paediatric HRQOL measurements: Physical, Emotional,Social and School Functioning.~Item Scaling:~5-point Likert scale from 0 (Never) to 4 (Almost always). 3-point scale: 0 (Not at all), 2 (Sometimes) and 4 (A lot) for the Young Child (ages 5-7).~Scores are transformed on a scale from 0 to 100 ( 0=100, 1=75, 2=50, 3=25, 4=0) Total Score: Sum of all the items over the number of items answered on all the Scales.~The values reported below are overall scores on Paediatric Quality of Life Inventory in Child/Teen Report. These scores were obtained by averaging scores for all the described subscales. The overall scores range between 0-100 with 0 = worst outcome and 100= best outcome" (NCT01027884)
Timeframe: Baseline and Week 52
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 2.46 |
| Idebenone | -1.34 |
(NCT01027884)
Timeframe: 52 Weeks
| Intervention | percentage of patients reporting AEs (Number) |
|---|---|
| Placebo | 94.1 |
| Idebenone | 93.8 |
"The change from Baseline to Week 52 in muscle strength as measured by Hand-Held Myometry (HHM) was performed following standardized procedures. As almost all patients were non-ambulatory, only analyses of upper limb muscle strength were performed. Results for elbow flexors and for elbow extensors are reported below.The highest value of 3 consecutive measurements with an interval of at least 10 seconds were recorded.~The HHM was measured using MicroFET2, a digital hand held muscle tester. The selected unit of measure was Newtons (N)." (NCT01027884)
Timeframe: Baseline and Week 52
| Intervention | Newtons (Mean) | |
|---|---|---|
| Elbow Flexors | Elbow Extensors | |
| Idebenone | -2.32 | 0.26 |
| Placebo | 0.13 | 1.32 |
2 trials available for idebenone and Respiration Disorders
1 other study available for idebenone and Respiration Disorders
| Article | Year |
|---|---|
Efficacy of idebenone in Duchenne muscular dystrophy.
Topics: Antioxidants; Humans; Male; Muscular Dystrophy, Duchenne; Respiration Disorders; Ubiquinone | 2015 |